共 192 条
[21]
Cleland JG(2022)Association of titin variations with late-onset dilated cardiomyopathy JAMA Cardiol. 37 1743-1750
[22]
Komajda M(2021)Prevalence and evolution of right ventricular dysfunction among different genetic backgrounds in dilated cardiomyopathy Can J Cardiol 10 10-1093
[23]
Wedel H(2021)Contemporary etiology and prognosis of dilated non-ischemic cardiomyopathy published online ahead of print, 2021 Aug 2] Minerva Cardiol Angiol. 23 1085-739
[24]
Pellicori P(2021)Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial Eur J Heart Fail 9 730-1437
[25]
Cleland JG(2007)Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials Eur J Heart Fail 22 1424-73
[26]
Zhang J(2020)Association between LD dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry Eur J Heart Fail 393 61-1710
[27]
Kallvikbacka-Bennett A(2019)Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial Lancet 103 1704-352
[28]
Urbinati A(2017)Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy Heart 27 345-456
[29]
Shah P(1996)Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy J Am Coll Cardiol 7 448-815
[30]
Martens P(2014)Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure Circ Heart Fail 22 808-undefined